Journal of the American Academy of Dermatology
Volume 61, Issue 5 , Pages 793-798 , November 2009

Randomized, double-blind, placebo-controlled evaluation of the efficacy of oral psoralen plus ultraviolet A for the treatment of plaque-type psoriasis using the Psoriasis Area Severity Index score (improvement of 75% or greater) at 12 weeks

  • S. Priya Sivanesan, MD, MPH

      Affiliations

    • Department of Dermatology, Pittsburgh University, Pittsburgh, Pennsylvania
    • ,
  • Shilpa Gattu, BS

      Affiliations

    • University of California, Irvine, California
    • ,
  • Judith Hong, MD

      Affiliations

    • Department of Dermatology, University of California, San Francisco, California
    • ,
  • Arianne Chavez-Frazier, MD

      Affiliations

    • Department of Dermatology, University of Texas Health Science Center, Houston, Texas
    • ,
  • Grace D. Bandow, MD

      Affiliations

    • Albert Einstein College of Medicine, New York, New York
    • ,
  • Farah Malick, MD

      Affiliations

    • Department of Dermatology, Wayne State University, Dearborn, Michigan
    • ,
  • Greg Kricorian, MD

      Affiliations

    • Amgen Pharmaceuticals, Orange County, California
    • ,
  • John Koo, MD

      Affiliations

    • Department of Dermatology, University of California, San Francisco, California
    • Corresponding Author InformationReprint requests: John Koo, MD, 515 Spruce St, San Francisco, CA 94118.

,Accepted 22 April 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Supported by Valeant Pharmaceuticals.

 Disclosure: Dr Koo has been a clinical researcher and/or consultant and/or speaker for Valeant, Allergan, Warner-Chilcott, Amgen, Biogen, Bristol-Myers Squibb, Centacor, Connetics, Elan, Astellas, Galderma, Genentech, GlaxoSmithKlein, Novartis, Roche, and Serono. Ms Gattu is a consultant for Coria Labs. Dr Kricorian was an employee at Amgen Pharmaceuticals. Drs Sivanesan, Hong, Chavez-Frazier, Bandow, and Malick have no conflicts of interest to declare.

 Interim data were presented orally at the American Academy of Dermatology 63rd Annual Meeting, New Orleans, LA, February 18-22, 2005.

PII: S0190-9622(09)00533-7

doi: 10.1016/j.jaad.2009.04.053

Journal of the American Academy of Dermatology
Volume 61, Issue 5 , Pages 793-798 , November 2009

Article Tools

* Image Usage & Resolution